Cite
HARVARD Citation
Gibb, A. et al. (2021). Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). British journal of haematology. pp. 63-71. [Online].